# The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017

S.I. 2017/632 · made 6 May 2017

Section 7(3) of the Misuse of Drugs Act 1971 requires regulations to be made to allow the use for medical purposes of the drugs which are subject to control under that Act. Section 7(3) does not apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order amends the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 (S.I. 2015/704) by inserting a synthetic opioid (U-47,700), several methylphenidate related materials and a number of designer benzodiazepines into Part 1 of the Schedule to that Order.

Made under: Misuse of Drugs Act 1971 (Section 7)

PDFs: Printed copy https://openlegislation.uk/misuse-of-drugs-designation-amendment-england-wales-and-scotland-order-2017/pdf/uksi_20170632_en.pdf; UK Explanatory Memorandum https://openlegislation.uk/misuse-of-drugs-designation-amendment-england-wales-and-scotland-order-2017/pdf/uksiem_20170632_en.pdf

## Introductory text

Dangerous Drugs, England And Wales
Dangerous Drugs, Scotland
Made 6th May 2017
Coming into force 31st May 2017
To be laid before Parliament 13th June 2017
The Secretary of State, in exercise of the powers conferred by sections 7(4) and 7(5) of the Misuse of Drugs Act 1971, and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 7(7) of that Act, makes the following Order:

## 1 Citation, commencement and extent

(1) This Order may be cited as the Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 and comes into force on 31st May 2017.
(2) This Order extends to England and Wales and Scotland.

## 2 Amendment to the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015

(1) The Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 is amended as follows.
(2) In paragraph 1(a) of Part 1 of the Schedule—
(a) before “Bufotenine” insert—
“Adinazolam (1-(8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine)
N-Benzyl-ethylphenidate
Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)”;
(b) after “Cathinone” insert—
“4’-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)”;
(c) after “Concentrate of poppy-straw” insert—
“Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)
3,4-Dichloroethylphenidate
3,4-Dichloromethylphenidate (3,4-DCMP)
Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Ethylnaphthidate
Ethylphenidate”;
(d) after “Eticyclidine” insert—
“Etizolam”;
(e) after “Etryptamine” insert—
“Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)
4-Fluoroethylphenidate
4-Fluoromethylphenidate
Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;
(f) after “Gamma-butyrolactone” insert—
“3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Isopropylphenidate (IPP or IPPD)”;
(g) after “Lysergide and other N-alkyl derivatives of lysergamide” insert—
“Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;
(h) after “Methcathinone” insert—
“4-Methylmethylphenidate
Methylmorphenate
Methylnaphthidate (HDMP-28)
Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)
Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2- one)
Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)
Propylphenidate”;
(i) after “Psilocin” insert—
“Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)”;
(j) after “3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)” insert—
“3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47,700)”.

## Signature

Sarah Newton
Parliamentary Under Secretary of State
Home Office
6th May 2017

## Explanatory note

(This note is not part of the Order)
Section 7(3) of the Misuse of Drugs Act 1971 requires regulations to be made to allow the use for medical purposes of the drugs which are subject to control under that Act. Section 7(3) does not apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order amends the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 (S.I. 2015/704) by inserting a synthetic opioid (U-47,700), several methylphenidate related materials and a number of designer benzodiazepines into Part 1 of the Schedule to that Order.
An impact assessment will be published alongside the Explanatory Memorandum on the legislation.gov.uk website.

---
Source: https://www.legislation.gov.uk/uksi/2017/632 (the official version)
Page: https://openlegislation.uk/misuse-of-drugs-designation-amendment-england-wales-and-scotland-order-2017
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.